a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products.
liquidia corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its print® technology. liquidia has developed yutrepia™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild). liquidia is also developing l606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in north america. the subsidiary liquidia pah provides for the commercialization of pharmaceutical products to treat pulmonary disease, such as generic treprostinil injection.
Company Information
- Industry
- Biotechnology Research
- Company Type
- Public Company
- Founded
- 2004
- Employee Range
- 51-200
- Revenue Range
- $10,000,000 - $15,000,000
Location
- Address
- 419 davis drive, suite 100
- City
- Morrisville
- Region
- North Carolina
- Postal Code
- 27560
- Country
- United States
